Impact of adjuvant therapy on quality of life in women with node-positive operable breast cancer

Lancet

Volumn 347, Issue 9011, 1996, Pages 1279-1284

  Hürny, Christoph ^a   Bernhard, Jürg ^b   Coates, Alan S ^c   Castiglione Gertsch, Monica ^b   Peterson, Harriet F ^d   Gelber, Richard D ^d   Forbes, John F ^e   Rudenstam, Carl Magnus ^f   Simoncini, Edda ^g   Crivellari, Diana ^h   Goldhirsch, Aron ⁱ   Senn, Hans Jörg ^j  

^a UNIVERSITY OF BERN   (Switzerland)

^b IBCSG Coordinating Center   (Switzerland)

^c ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^d HARVARD MEDICAL SCHOOL   (United States)

^e NEWCASTLE MATER HOSPITAL   (Australia)

^f SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^g Servizio di Oncologia   (Italy)

^h CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

ⁱ Ospedale Civico Lugano   (Switzerland)

^j Kantonosspital   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; TAMOXIFEN;

ADJUVANT CHEMOTHERAPY; ADULT; APPETITE; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COPING BEHAVIOR; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MOOD; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SELF EVALUATION; WELLBEING;

EID: 9244228456     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)90936-8     Document Type: Article

References (31)

1. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women. Lancet 1992; 339: 1-15, 71-85.
2. Beral V, Hermon C, Reeves G, Peto R. Sudden fall in breast cancer death rates in England and Wales. Lancet 1995; 345: 1642-43.
3. Editorial. Quality of life and clinical trials. Lancet 1995; 346: 1-2.
4. The International Breast Cancer Study Group. Duration and reintroduction of adjuvant chemotherapy for node-positive premenopausal breast cancer patients. J Clin Oncol 1996 (in press).
5. Hürny C, Bernhard J, Gelber RD, et al. Quality of life measures for patients receiving adjuvant therapy for breast cancer: an international trial. International Breast Cancer Study Group. Eur J Cancer 1992; 28: 118-24.
6. Priestman TJ, Baum M. Evaluation of quality of life in patients receiving treatment for advanced brest cancer. Lancet 1976; i: 899-901.
7. Coates AS, Gebski V, Bishop JF, et al. Improving the quality of life in advanced breast cancer: a comparison of continuous and intermittent treatment strategies. N Engl J Med 1987; 317: 1490-95.
8. Hürny C, Bernhard J, Bacchi M, et al. The Perceived Adjustment to Chronic Illness Scale (PACIS): a global indicator of coping for operable breast cancer patients in clinical trials. Support Care Cancer 1993; 1: 200-08.
9. Coates AS, Fischer-Dillenbeck C, McNeil DR, et al. On the receiving end, II: linear analogue self-assessment in the evaluation of quality of life of cancer patients. Eur J Cancer Clin Oncol 1983; 19: 1633-38.
10. Coates AS, Glasziou PP, McNeil D. On the receiving end, III: measurement of quality of life during cancer chemotherapy. Ann Oncol 1990; 1: 213-17.
11. Coates AS, Gebski V, Signorini D, et al. Prognostic value of quality-of-life scores during chemotherapy for advanced breast cancer: Australian New Zealand Breast Cancer Trials Group. J Clin Oncol 1992; 10: 1833-38.
12. Coates AS, Thomson D, McLeod GR, et al. Prognostic value of quality of life scores in a trial of chemotherapy with or without interferon in patients with metastatic melanoma. Eur J Cancer 1993; 29A: 1731-34.
13. Zersen DV. Clinical self-rating scales (CSRS) of the Munich Psychiatric Information System (PSYCHIS Muenchen). In: Sartorius N, Ban TA, eds. Assessment of depression. Berlin: Springer, 1986: 270-303.
14. Hürny C, Bernhard J, Coates AS, et al. Responsiveness of a single-item indicator versus a multi-item scale: assessment of emotional wellbeing in an international adjuvant breast cancer trial. Med Care 1996; 34: 234-48.
15. Hürny C, Bernhard J, Coates AS, et al. Timing of baseline quality of life assessment in an international adjuvant breast cancer trial: is effect on patient self-estimation. Ann Oncol 1994; 5: 65-74.
16. van Knippenberg FCE, de Haes JCJM. Variance and dissent: measuring the quality of life of cancer patients: psychometric properties of instruments. J Clin Epidemiol 1988; 41: 1043-53.
17. Donovan K, Sanson-Fisher RW, Redman S. Measuring quality of life in cancer patients. J Clin Oncol 1989; 7: 959-68.
18. Gill TM, Feinstein AR. A critical appraisal of the quality of quality-of-life measurements. JAMA 1994; 272: 619-26.
19. Hürny C, Bernhard J, Joss R, et al. Feasibility of quality of life assessment in a randomized phase III trial of small cell lung cancer - a lesson from the real world - the Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 1992; 3: 825-31.
20. Bernhard J, Hürny C, Coates AS, Gelber RD. Applying quality of life principles in international cancer clinical trials. In: Spilker B, ed. Quality of life and pharmacoeconomics in clinical trials. New York: Lippincott-Raven Publishers, 1996: 693-705.
21. Butow PN, Coates AS, Dunn S, Bernhard J, Hürny C. On the receiving end. IV: validation of quality of life indicators. Ann Oncol 1991; 2: 597-603.
22. Priestman TJ, Baum M, Jones V, Forbes JF. Comparative trial of endocrine versus cytotoxic treatment in advanced breast cancer. BMJ 1977; i: 1248-50.
23. Tannock IF, Boyd NF, DeBoer G, et al. A randomized trial of two dose levels of cyclophosphamide, methotrexate and fluorouracil chemotherapy for patients with metastatic breast cancer. J Clin Oncol 1988; 6: 1377-87.
24. Fraser SCA, Dobbs HJ, Ebbs SR, Fallowfield LJ, Bates T, Baum M. Combination or mild single agent chemotherapy for advanced breast cancer? CMF vs epirubicin measuring quality of life. Br J Cancer 1993; 67: 402-06.
25. Goldhirsch A, Gelber RD, Simes RJ, Glasziou PP, Coates AS. Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis. J Clin Oncol 1989; 7: 36-44.
26. Fetting JH. Evaluating quality and quantity of life in breast cancer adjuvant trials. J Clin Oncol 1988; 6: 1795-97.
27. Fairclough D, Gelber RD. Quality of life: statistical issues and analysis. In: Spilker B, ed. Quality of life and pharmacoeconomics. New York: Lippincott-Raven Publishers, 1996: 427-35.
28. Irvine D, Brown B, Crooks D, Roberts J, Browne G. Psychosocial adjustment in women with breast cancer. Cancer 1991; 67: 1097-117.
29. Mor V, Malin M, Allen S. Age differences in the psychosocial problems encountered by breast cancer patients. Monogr Natl Cancer Inst 1994; 16: 191-97.
30. Roberts CS, Cox CE, Reintgen DS, Baile WF, Gibertini M. Influence of physician communication on newly diagnosed breast patients' psychologic adjustment and decision-making. Cancer 1994; 74: 336-41.
31. Razavi D, Farvacques C, Delvaux N. Psychosocial correlates of oestrogen and progesterone receptors in breast cancer. Lancet 1990; 335: 931-33.